Australian Industry Signs Deal To Fund Access To Innovative New Drugs
Plans Include More Horizon Scanning Of New Therapies In Pipeline
Hot on the heels of Australia’s plan to overhaul the National Medicines Policy comes a new deal with the pharmaceutical industry to make new drugs available as soon as possible after approval and get patients more closely involved in reimbursement processes.
You may also be interested in...
Stakeholders are being asked to say what they think of plans to future-proof the framework that governs access to medicines and is intended to help bolster the pharmaceutical sector.
A fresh five-year strategic agreement struck between Australian off-patent industry association the GBMA and the country’s government offers sustainability and stability for Australia’s generics sector, with the body committing to holding safety stocks of certain drugs within the country to protect against potential shortages in the context of the COVID-19 pandemic.
The EU vaunts its vaccine donations and starts building resilience against future health threats, and the UK MHRA says Moderna can be used as a booster dose. Aviptadil has received scientific advice from the MHRA for its potential use as a treatment for COVID-19 patients.